Cargando…
Clinical Benefits of Olaparib in Mexican Ovarian Cancer Patients With Founder Mutation BRCA1-Del ex9-12
Background: Ovarian cancer (OC) is gynecologic cancer with the highest mortality rate. It is estimated that 13–17% of ovarian cancers are due to heritable mutations in BRCA1 and BRCA2. The BRCA1 (BRCA1-Del ex9-12) Mexican founder mutation is responsible for 28–35% of the cases with ovarian cancer. T...
Autores principales: | Gallardo-Rincón, Dolores, Montes-Servín, Edgar, Alamilla-García, Gabriela, Montes-Servín, Elizabeth, Bahena-González, Antonio, Cetina-Pérez, Lucely, Morales Vásquez, Flavia, Cano-Blanco, Claudia, Coronel-Martínez, Jaime, González-Ibarra, Ernesto, Espinosa-Romero, Raquel, María Alvarez-Gómez, Rosa, Pedroza-Torres, Abraham, Castro-Eguiluz, Denisse |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207274/ https://www.ncbi.nlm.nih.gov/pubmed/35734436 http://dx.doi.org/10.3389/fgene.2022.863956 |
Ejemplares similares
-
Clinical Evaluation of BRCA1/2 Mutation in Mexican Ovarian Cancer Patients
por: Gallardo-Rincón, Dolores, et al.
Publicado: (2019) -
Impact of metabolic syndrome on the risk of endometrial cancer and the role of lifestyle in prevention
por: Pérez-Martín, Alejandra Rocío, et al.
Publicado: (2022) -
The health system and access to treatment in patients with cervical cancer in Mexico
por: Arango-Bravo, Eder A., et al.
Publicado: (2022) -
Mexican BRCA1 founder mutation: Shortening the gap in genetic assessment for hereditary breast and ovarian cancer patients
por: Fragoso-Ontiveros, Veronica, et al.
Publicado: (2019) -
Olaparib and somatic BRCA mutations
por: George, Angela, et al.
Publicado: (2017)